Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

NITI Aayog member, Dr VK Paul, who is the govt's top Covid-19 adviser on Thursday said that recipients must stick to the same dose of vaccine as their first one. But, in case people have got different jabs, there is no cause for concern. 
His clarification comes after reports that 20 villagers in Uttar Pradesh&rsquo;s Siddharthnagar district were administered a dose of Covaxin after the first dose of Covishield, triggering fear of side-effects among people. Dr Paul added that two different doses are safe and the govt is mulling a mix and match of vaccine doses on a trial basis. 
Studies meanwhile are being conducted globally, to see the possible outcome of mixing doses of the Pfizer and AstraZeneca vaccines. A trial on 600 participants showed that if Pfizer's mRNA vaccine is given as the second dose to beneficiaries who got AstraZeneca's shot as their first dose, it improved immune response significantly with mild side-effects.
Canada, Finland, France, Norway, Sweden, Spain, and South Korea have allowed the use of a different vaccine for the second dose for complete Covid-19 vaccination if the first dose was of AstraZeneca vaccine. The US has allowed mixing of Pfizer and Moderna vaccines asking the recipients to take the two shots with a gap of 28 days.

2 doses of different vaccines safe, govt thinking about it: Covid task force chief

Govt's&nbsp;Covid&nbsp;adviser: govt mulling mixing two different doses of vaccine
Dr VK Paul: recipients should ideally stick to the same dose of vaccine
In case people got different jabs, there is no cause for concern: govt
20 villagers in UP's Siddharthnagar district were inoculated with a mix
Dr Paul: govt mulling a mix and match of vaccine doses on a trial basis
Studies underway globally to see the possible outcome of a&nbsp;vaccine mix
Trials conducted with Pfizer as 2nd dose after AstraZeneca&nbsp;as dose 1
Trials showed&nbsp;improved immune response, with mild side-effects
Canada, Finland, France, Norway, Sweden, have allowed vaccine mixes
US allowed mixing of Pfizer and Moderna vaccines with a gap of 28 days

NITI Aayog member, Dr VK Paul, who is the govt's top Covid-19 adviser on Thursday said that recipients must stick to the same dose of vaccine as their first one. But, in case people have got different jabs, there is no cause for concern. 
His clarification comes after reports that 20 villagers in Uttar Pradesh&rsquo;s Siddharthnagar district were administered a dose of Covaxin after the first dose of Covishield, triggering fear of side-effects among people. Dr Paul added that two different doses are safe and the govt is mulling a mix and match of vaccine doses on a trial basis. 
Studies meanwhile are being conducted globally, to see the possible outcome of mixing doses of the Pfizer and AstraZeneca vaccines. A trial on 600 participants showed that if Pfizer's mRNA vaccine is given as the second dose to beneficiaries who got AstraZeneca's shot as their first dose, it improved immune response significantly with mild side-effects.
Canada, Finland, France, Norway, Sweden, Spain, and South Korea have allowed the use of a different vaccine for the second dose for complete Covid-19 vaccination if the first dose was of AstraZeneca vaccine. The US has allowed mixing of Pfizer and Moderna vaccines asking the recipients to take the two shots with a gap of 28 days.

The World Health Organization has approved the coronavirus vaccine developed by AstraZeneca. It will be a boost for poorer countries where millions of doses are set to be distributed.&nbsp;The AstraZeneca shot, which is easier to store and transport than some of its rivals, will account for almost all the doses set to be shipped under Covax, an international programme designed to ensure that poor countries do not miss out. While inoculation drives have been gaining pace, with nearly 172 million vaccine doses given worldwide, most of the jabs have so far gone to richer countries.

WHO nod to AstraZeneca Covid vaccine for distribution in poor countries under Covax

The World Health Organization has approved the coronavirus vaccine developed by AstraZeneca. It will be a boost for poorer countries where millions of doses are set to be distributed

WHO nod to AstraZeneca Covid vaccine for distribution under Covax

The World Health Organization has approved the coronavirus vaccine developed by AstraZeneca. It will be a boost for poorer countries where millions of doses are set to be distributed.&nbsp;The AstraZeneca shot, which is easier to store and transport than some of its rivals, will account for almost all the doses set to be shipped under Covax, an international programme designed to ensure that poor countries do not miss out. While inoculation drives have been gaining pace, with nearly 172 million vaccine doses given worldwide, most of the jabs have so far gone to richer countries.

A UN-backed programme to make Covid-19 vaccines available to the neediest people worldwide, especially in poor countries, announced that it plans an initial distribution of some 100 million doses by the end of March and more than 200 million more by the end of June. The COVAX Facility, which is seeking the fair distribution of vaccines at a time of short supplies, said that nearly all of the doses expected for the first phase will come from British-Swedish drugmaker AstraZeneca and its partner, the Serum Institute of India. COVAX has faced challenges as rich countries have scooped up vaccine supplies undercutting WHO's goal of equitable vaccine distribution.
&nbsp;

UN programme seeks rollout of 100 mn Covid vaccine doses for poor

COVAX&nbsp;Facility programme plans an initial distribution of some 100 million doses of Covid&nbsp;vaccine by the end of March and more than 200 million more by the end of June

UN programme seeks rollout of 100 mn Covid vaccine doses for poor 

A UN-backed programme to make Covid-19 vaccines available to the neediest people worldwide, especially in poor countries, announced that it plans an initial distribution of some 100 million doses by the end of March and more than 200 million more by the end of June. The COVAX Facility, which is seeking the fair distribution of vaccines at a time of short supplies, said that nearly all of the doses expected for the first phase will come from British-Swedish drugmaker AstraZeneca and its partner, the Serum Institute of India.

A UN-backed programme to make Covid-19 vaccines available to the neediest people worldwide, especially in poor countries, announced that it plans an initial distribution of some 100 million doses by the end of March and more than 200 million more by the end of June. The COVAX Facility, which is seeking the fair distribution of vaccines at a time of short supplies, said that nearly all of the doses expected for the first phase will come from British-Swedish drugmaker AstraZeneca and its partner, the Serum Institute of India. COVAX has faced challenges as rich countries have scooped up vaccine supplies undercutting WHO's goal of equitable vaccine distribution.
&nbsp;

China extends use of its Covid-19 vaccines to 3 more cities

PTI,&nbsp;Beijing: Days after joining the World Health Organisation&rsquo;s (WHO) COVAX alliance to equitably distribute COVID-19 vaccines across the world, China has stepped up the usage of its coronavirus vaccines to three more cities for urgent use.
Three more cities in East China's Zhejiang Province are stepping up efforts to offer COVID-19 vaccines for urgent use, with priority being given to key groups in need before they can be rolled out to the general public, official media reports here said.
The cities of Yiwu, Ningbo and Shaoxing are targeting key groups with urgent need for vaccinations against COVID-19 following the city of Jiaxing, state-run Global Times quoted another daily, The Paper, as reporting on Saturday.
Earlier on Thursday, health authorities in Jiaxing announced that the city has been administering inactivated COVID-19 vaccines among high-risk groups and will gradually offer it to ordinary citizens for urgent use.
According to the report, the emergency vaccinations have officially kicked off in Yiwu, an internationally renowned manufacturing hub.
On Friday afternoon, about 20 people visited the community health centre to receive vaccinations against COVID-19 within an hour.
Most of the recipients are set to go abroad or have plans to go abroad in the near future, The Paper reported.
The Yiwu health authorities said the COVID-19 shots have arrived in the local medical system and are limited to a small part of the population in need of emergency vaccination, including frontline medical staff, personnel who ensure the city's basic operation, and public officials who need to travel to high-risk countries and regions on official duties, the Global Times report said.
Yiwu also has no plans to make the vaccine available to the general public at the time, but may consider offering the vaccination to the public if there is an abundant supply when the vaccine is officially on the market, it said.
China in a surprise move on October 9 joined the WHO's COVAX alliance to equitably distribute COVID-19 ending speculation that it plans to supply its vaccines to developing countries to improve its image dented by pandemic since it emerged in Wuhan in December last year.
All the 11 vaccines in China are in various stages of trials and await final approval.
The COVAX is a global initiative aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines, once they are licensed and approved.
China has roped in more than a dozen countries to conduct the final phase trials of Chinese-made experimental COVID-19 vaccines and even started vaccinating thousands of emergency workers.
Yang Sheng, Deputy Director of the National Medical Products Administration's drug registration bureau, said earlier that four China-developed COVID-19 vaccines have begun the final stage of human trials overseas after obtaining approval from foreign authorities.
China has been focusing on developing five types of vaccines, and each method has at least one entering clinical trials.
In total, 11 vaccine candidates are in different stages of testing, Yang has been quoted by the official media earlier.
Zheng Zhongwei, head of China's vaccine development task force, said China's annual capacity to make COVID-19 vaccines was expected to reach 610 million doses this year and one billion doses by 2021.
The WHO said nine candidate vaccines are currently being evaluated for inclusion in the COVAX Facility.
They include two from China, two from the US, one from the Republic of Korea, one from Britain and Northern Ireland and one global, multi-manufacturer partnership.
Two of these are in phase I trials, two are technology transfers and the remainder are at the discovery stage.
The coronavirus has so far claimed 4,634 lives with 85,672 confirmed infections in China.

Days after joining the World Health Organisation&rsquo;s alliance for equitable distribute Covid-19 vaccines across the globe, China has stepped up the usage of its coronavirus vaccines to three more cities for urgent use. Reports said&nbsp; three more cities in East China's Zhejiang Province are stepping up efforts to offer Covid-19 vaccines for urgent use, with priority being given to key groups in need before they can be rolled out to the general public. The cities of Yiwu, Ningbo and Shaoxing are targeting key groups with urgent need for vaccinations against Covid-19 following the city of Jiaxing.&nbsp;All the 11 vaccines in China are in various stages of trials and await final approval.

PTI,&nbsp;Beijing: Days after joining the World Health Organisation&rsquo;s (WHO) COVAX alliance to equitably distribute COVID-19 vaccines across the world, China has stepped up the usage of its coronavirus vaccines to three more cities for urgent use.
Three more cities in East China's Zhejiang Province are stepping up efforts to offer COVID-19 vaccines for urgent use, with priority being given to key groups in need before they can be rolled out to the general public, official media reports here said.
The cities of Yiwu, Ningbo and Shaoxing are targeting key groups with urgent need for vaccinations against COVID-19 following the city of Jiaxing, state-run Global Times quoted another daily, The Paper, as reporting on Saturday.
Earlier on Thursday, health authorities in Jiaxing announced that the city has been administering inactivated COVID-19 vaccines among high-risk groups and will gradually offer it to ordinary citizens for urgent use.
According to the report, the emergency vaccinations have officially kicked off in Yiwu, an internationally renowned manufacturing hub.
On Friday afternoon, about 20 people visited the community health centre to receive vaccinations against COVID-19 within an hour.
Most of the recipients are set to go abroad or have plans to go abroad in the near future, The Paper reported.
The Yiwu health authorities said the COVID-19 shots have arrived in the local medical system and are limited to a small part of the population in need of emergency vaccination, including frontline medical staff, personnel who ensure the city's basic operation, and public officials who need to travel to high-risk countries and regions on official duties, the Global Times report said.
Yiwu also has no plans to make the vaccine available to the general public at the time, but may consider offering the vaccination to the public if there is an abundant supply when the vaccine is officially on the market, it said.
China in a surprise move on October 9 joined the WHO's COVAX alliance to equitably distribute COVID-19 ending speculation that it plans to supply its vaccines to developing countries to improve its image dented by pandemic since it emerged in Wuhan in December last year.
All the 11 vaccines in China are in various stages of trials and await final approval.
The COVAX is a global initiative aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines, once they are licensed and approved.
China has roped in more than a dozen countries to conduct the final phase trials of Chinese-made experimental COVID-19 vaccines and even started vaccinating thousands of emergency workers.
Yang Sheng, Deputy Director of the National Medical Products Administration's drug registration bureau, said earlier that four China-developed COVID-19 vaccines have begun the final stage of human trials overseas after obtaining approval from foreign authorities.
China has been focusing on developing five types of vaccines, and each method has at least one entering clinical trials.
In total, 11 vaccine candidates are in different stages of testing, Yang has been quoted by the official media earlier.
Zheng Zhongwei, head of China's vaccine development task force, said China's annual capacity to make COVID-19 vaccines was expected to reach 610 million doses this year and one billion doses by 2021.
The WHO said nine candidate vaccines are currently being evaluated for inclusion in the COVAX Facility.
They include two from China, two from the US, one from the Republic of Korea, one from Britain and Northern Ireland and one global, multi-manufacturer partnership.
Two of these are in phase I trials, two are technology transfers and the remainder are at the discovery stage.
The coronavirus has so far claimed 4,634 lives with 85,672 confirmed infections in China.

covax facility

Categories